Latest Breaking News On - Patient protection committee - Page 1 : comparemela.com

Artificial heart: Carmat will resume its facilities in France

The French company Carmat will restart the implantations of its artificial heart in France, after having received the regulatory authorizations necessary to resume its clinical study in France,…

CARMAT announces that it has received regulatory approvals to resume its clinical study in France

CARMAT (FR0010907956, ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, designed to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, announced today that it has been granted the necessary regulatory approvals from the .

Legislative panel preps mental health bills for 2023 session

Pherecydes Pharma Obtains ANSM Approval for its PhagoDAIR Program, the World's First Study in Precision Phage Therapy Seite 1

22.12.2021 - Regulatory News: Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has obtained ANSM (French . Seite 1

Pherecydes Pharma Obtains ANSM Approval for its PhagoDAIR Program, the World's First Study in Precision Phage Therapy

PhagoDAIR is a phase I/II clinical study with anti-Staphylococcus aureus phages in the treatment of osteoarticular infections of prostheses caused by this bacterium Patient enrollment should